Form 4: Cytokinetics Director Acquires Shares in Lieu of Cash Retainer

Edward M. Kaye, a director at Cytokinetics Inc, acquired 237 shares of common stock on October 1, 2024, in lieu of a cash retainer payment.

Summary

• On October 1, 2024, Edward M. Kaye, a director of Cytokinetics Inc., acquired 237 shares of common stock.
• The acquisition was made in lieu of a cash retainer payment at a price of $52.6 per share.
• Following the transaction, Kaye directly owns 25,382 shares of Cytokinetics Inc.
• The transaction was reported on October 3, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A director taking shares instead of cash could indicate confidence, but it's a small transaction.

Positives

• A director taking shares in lieu of cash may signal confidence in the company's future prospects.

Industry Context

Insider transactions are closely monitored as they can provide insights into a company's prospects. Directors acquiring shares may be seen as a positive signal.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates